Anti-angiogenesis target therapy for advanced osteosarcoma (Review)

Area of Science:

• Oncology
• Medical Research

Background:

• Osteosarcoma (OS) presents limited treatment options, especially for metastatic or unresectable cases.
• While multi-agent chemotherapy improved survival in the 1980s, response rates in relapsed/advanced OS remain poor.
• Vascular Endothelial Growth Factor Receptor (VEGFR) expression and circulating VEGF levels are linked to OS outcomes and lung metastasis.

Purpose of the Study:

• To review the latest advancements in anti-angiogenesis therapy for osteosarcoma.
• To discuss current clinical strategies for improving progression-free survival in advanced OS.

Main Methods:

• Literature review of anti-angiogenesis therapies in osteosarcoma.
• Analysis of clinical trials and therapeutic strategies for advanced OS.

Main Results:

• Progress in second-line therapy for advanced OS, like sorafenib, has been incremental.
• The efficacy of therapies such as muramyltripeptide phosphatidyl-ethanolamine in refractory OS is debated.
• Personalized molecular profiling has not significantly altered therapeutic outcomes for advanced OS.

Conclusions:

• Anti-angiogenesis therapy remains a critical area for improving outcomes in osteosarcoma.
• Further research and novel therapeutic strategies are needed to overcome treatment limitations in advanced OS.